Lifibrol

N/A

Report date: 2022/09/05 20:00:48
NME

Base Information

Drug NameLifibrol
Drug Alias Name利非贝罗K-12148U-83860
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCholesterol synthesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsHyperlipoproteinemiasHypercholesterolemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Hospital Bonn
Active IndicationsN/A
Inactive IndicationsHyperlipoproteinemiasHypercholesterolemia

Other Information

ATC CodeN/A
Related LinksKEGG